Balaxi Pharmaceuticals Limited

BALAXI

INE618N01014

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 12:31:57 18/05/2024 pm IST			5-day change	1st Jan Change
654.6 ^INR	+0.93%		+5.56%	+51.41%

09/05	Balaxi Pharmaceuticals Limited Appoints Mahesh Inani as the Compliance Officer	CI
08/05	Balaxi Pharmaceuticals Limited Announces Resignation of Purnima Singh Kamble as Independent Director	CI

Balaxi Pharmaceuticals Limited Incorporates New Wholly Owned Subsidiary in Chile

February 14, 2024 at 03:13 pm IST

Balaxi Pharmaceuticals Limited, has incorporated a new Wholly Owned Subsid subsidiary in Chile by the name Balaxi Pharmaceuticals Chile SPA. Consequent to the incorporation, Balaxi Pharmaceuticals ChileSPA has become a Wholly Owned Step-Down Subsidiary of the Company.

Latest news about Balaxi Pharmaceuticals Limited

Balaxi Pharmaceuticals Limited Appoints Mahesh Inani as the Compliance Officer	09/05	CI
Balaxi Pharmaceuticals Limited Announces Resignation of Purnima Singh Kamble as Independent Director	08/05	CI
Balaxi Pharmaceuticals Limited Announces Resignation of Udayan Shukla as Company Secretary and Compliance Officer	04/05	CI
Balaxi Pharmaceuticals Limited Incorporates New Wholly Owned Subsidiary in Chile	14/02	CI
Balaxi Pharmaceuticals Limited Announces Update on Company's Pharmaceutical Formulation Plant	09/02	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	02/11	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	03/23/03	CI
Balaxi Pharmaceuticals Limited agreed to acquire Balaxi Healthcare Ecuador S.A.S. for $0.04 million.	03/23/03	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	29/23/29	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	01/23/01	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	05/22/05	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	02/22/02	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	23/22/23	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	09/22/09	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	28/21/28	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	17/21/17	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	20/21/20	CI
Balaxi Pharmaceuticals Limited Announces Resignation of Rakesh Khanna as an Additional Director (Independent Category)	02/21/02	CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	19/21/19	CI
Balaxi Ventures Limited will Change its Name to Balaxi Pharmaceuticals Limited	20/20/20	CI
Balaxi Pharmaceuticals Limited Appoints Chinta Shalini as Company Secretary and Compliance Officer	13/20/13	CI
Balaxi Ventures to Expand into Three Central American Markets	30/20/30	CI
Balaxi Ventures Limited Announces the Resignation of Nidhin Jose as Company Secretary & Compliance Officer	21/20/21	CI
Balaxi Ventures Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	22/20/22	CI

Chart Balaxi Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across Latin America and Africa. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It has a portfolio across multiple therapeutic segments, stock & sell models, and supplies branded and generic medicines. The Companyâs products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its subsidiary is Balaxi Global DMCC, Dubai.

Sector

Pharmaceuticals

Calendar

31/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
BALAXI PHARMACEUTICALS LIMITED	+51.41%	79.09M
MCKESSON CORPORATION	+21.93%	73.38B
SINOPHARM GROUP CO. LTD.	+7.33%	8.78B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+10.34%	8.59B
HUADONG MEDICINE CO., LTD	-19.80%	8.06B
H. LUNDBECK A/S	+14.16%	5.26B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+12.70%	4.17B
EBOS GROUP LIMITED	-0.03%	4.21B
GALENICA AG	-2.54%	3.89B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+24.00%	3.71B

Pharmaceuticals Wholesale